Treatment of lycorine on SCID mice model with human APL cells.

Treatment of lycorine on SCID mice model with human APL cells.
复制标题

DOI:
10.1016/j.biopha.2007.01.003
复制
发表时间:
2007-05
期刊:
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
影响因子:
--
通讯作者:
Hu WX
Hu WX
中科院分区:
其他
文献类型:
--
作者:
Liu J;Li Y;Tang LJ;Zhang GP;Hu WX

文献摘要

参考文献

被引文献

相似文献

石蒜碱是从石蒜科植物中提取的一种天然生物碱,在体外具有抗白血病作用。为了确定石蒜碱在体内是否具有抗肿瘤作用,本研究进行了一系列实验。将HL-60细胞(5×106)静脉接种。严重联合免疫缺陷(SCID)小鼠接受照射(全身接受200cGyχ照射)后。治疗从第2天到第6天,第14天到第18天,每天一次。石蒜碱(5或10 mg/kg/d,ip)。石蒜碱可降低未成熟颗粒白细胞和单核细胞在外周血细胞中的比例,且石蒜碱两组小鼠的平均存活时间均长于对照组。与异步组和阿糖胞苷(Ara-C)组(20 mg/kg/d,i.p.)石蒜碱治疗组疗效较好。石蒜碱也被发现可以减轻肿瘤细胞对肝脏、骨骼和骨髓的渗透。接种HL-60细胞的SCID小鼠再用石蒜碱治疗,未观察到严重的不良反应。这项研究表明,石蒜碱在人类白血病异种移植模型中测试时,似乎在体内显示出抗肿瘤活性,是治疗急性早幼粒细胞白血病的有效药物。
In our previous study, lycorine, a natural alkaloid extracted from Amaryllidaceae, exhibited anti-leukemia effects in vitro. To determine whether lycorine has an anti-tumor effect in vivo, a series of experiments were carried out in this study. HL-60 cells (5 × 106) were inoculated i.v. into severe combined immuno-deficiency (SCID) mice after these mice had been irradiated (total body receiving 200 cGy χ irradiation). Treatment was given once a day from day 2 to 6, and from day 14 to 18. Lycorine (5 or 10 mg/kg/day i.p.) was found to decrease the percentages of immature granular leukocytes and of monocytes among the peripheral blood cells, and the mean survival time of both lycorine-treated groups was longer than that of the control group. Compared with the asynchronous and cytosine arabinoside- (Ara-C) treated (20 mg/kg/day i.p.) group, treatment with lycorine was more effective. Lycorine was also found to alleviate the infiltration of tumor cells into the liver, bone, and marrow. When SCID mice inoculated with HL-60 cells were then treated with lycorine, no severe adverse effects were observed. This study revealed that lycorine, when tested in the human leukemia xenograft models, appears to exhibit anti-tumor activity in vivo and is a useful therapy against acute promyelocytic leukemia.
DOI: 10.1016/j.antiviral.2005.02.007
发表时间: 2005-07
期刊: Antiviral research
影响因子: 7.6
作者:
Li SY;Chen C;Zhang HQ;Guo HY;Wang H;Wang L;Zhang X;Hua SN;Yu J;Xiao PG;Li RS;Tan X
通讯作者: Tan X
DOI: 10.1016/j.canlet.2004.01.012
发表时间: 2004-05-10
期刊: CANCER LETTERS
影响因子: 9.7
作者:
Kobayakawa, J;Sato-Nishimori, F;Matsukawa, Y
通讯作者: Matsukawa, Y
DOI: 10.1016/j.febslet.2004.10.095
发表时间: 2004-12-17
期刊: FEBS LETTERS
影响因子: 3.5
作者:
Liu, J;Hu, WX;Li, Y
通讯作者: Li, Y
DOI: 10.1016/s0304-3835(96)04519-3
发表时间: 1997-01-01
期刊: CANCER LETTERS
影响因子: 9.7
作者:
Murray, S;Schell, K;Albertini, MR
通讯作者: Albertini, MR
DOI: 10.1016/j.leukres.2005.03.019
发表时间: 2005-10-01
期刊: LEUKEMIA RESEARCH
影响因子: 2.7
作者:
Henschler, R;Göttig, S;Fichtner, I
通讯作者: Fichtner, I